Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Wang, M. (Michael) | - |
dc.creator | Rule, S. (Simon) | - |
dc.creator | Zinzani, P.L. (P. L.) | - |
dc.creator | Goy, A. (Andre) | - |
dc.creator | Casasnovas, R. O. (René Olivier) | - |
dc.creator | Smith, S.D. (Stephen D.) | - |
dc.creator | Damaj, G. (Gandhi) | - |
dc.creator | Doorduijn, J.K. (Jeanette K.) | - |
dc.creator | Lamy, T. (Thierry) | - |
dc.creator | Morschhauser, F. (Franck) | - |
dc.creator | Panizo, C. (Carlos) | - |
dc.creator | Shah, B. (Bijal) | - |
dc.creator | Davies, A. (Andrew) | - |
dc.creator | Eek, R. (Richard) | - |
dc.creator | Dupuis, J. (Jehan) | - |
dc.creator | Jacobsen, E. (Eric) | - |
dc.creator | Kate, A.P. (Arnon P.) | - |
dc.creator | Le-Gouill, S. (Steven) | - |
dc.creator | Oberic, L. (Lucie) | - |
dc.creator | Robak, T. (Tadeusz) | - |
dc.creator | Jain, P. (Preetesh) | - |
dc.creator | Frigault, M.M. (Melanie M.) | - |
dc.creator | Raquel | - |
dc.creator | Nguyen, D. (Dorothy) | - |
dc.creator | Patel, P (Priti) | - |
dc.creator | Yin, M. (Ming) | - |
dc.creator | Dlugosz-Danecka, M. (Monika) | - |
dc.date.accessioned | 2021-12-09T10:44:24Z | - |
dc.date.available | 2021-12-09T10:44:24Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Wang, M. (Michael); Rule, S. (Simon); Zinzani, P.L. (P.L.); et al. "Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma". Leukemia. 33, 2019, 2762 - 2766 | es_ES |
dc.identifier.issn | 0887-6924 | - |
dc.identifier.uri | https://hdl.handle.net/10171/62620 | - |
dc.description.abstract | Bruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1–4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity [5]. Acalabrutinib was approved in 2017 by the US Food and Drug Administration for the treatment of relapsed/refractory MCL based on clinical data from the open-label, multicenter, phase 2 ACE-LY-004 study of acalabrutinib 100 mg twice daily [1]. Here, we present updated results from the ACE-LY-004 study after a median 26-month follow-up. Eligibility criteria and study design were published previously (Supplementary methods) [1]. Analysis of minimal residual disease (MRD) was conducted after complete response (CR) or partial response (PR) was achieved using the quantitative ClonoSEQ next-generation sequencing (5 × 10−6 ) assay (Adpative Biotechnologies, Seattle, WA, USA) in consenting patients with available paired archival tumor and whole blood samples. Data are updated as of February 12, 2018. | es_ES |
dc.description.sponsorship | This study was sponsored by Acerta Pharma, a member of the AstraZeneca Group. We thank the patients who participated in this trial and their families and caregivers; the investigators and coordinators at each study site; and the Acerta Pharma study team, including Sofia Wong. Medical writing assistance was provided by Stephanie Morgan of Team9Science and funded by Acerta Pharma. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer Science and Business Media LLC | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Bruton tyrosine kinase (BTK) | es_ES |
dc.subject | Mantle cell lymphoma (MCL) | es_ES |
dc.subject | Acalabrutinib | es_ES |
dc.subject | Clinical data | es_ES |
dc.title | Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This article is licensed under a Creative Commons Attribution 4.0 International License | es_ES |
dc.identifier.doi | 10.1038/s41375-019-0575-9 | - |
dadun.citation.endingPage | 2766 | es_ES |
dadun.citation.publicationName | Leukemia | es_ES |
dadun.citation.startingPage | 2762 | es_ES |
dadun.citation.volume | 33 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.